DC-CIK联合化疗治疗晚期胃癌的近期疗效

Short-term efficacy of DC-CIK biotherapy combined with chemotherapy for patients with advanced gastric cancer

目的观察树突状细胞(dendritic cell,DC)与细胞因子诱导的杀伤细胞(cytokine induced killer cell,CIK)联合化疗治疗晚期胃癌的近期疗效。方法分析68例经病理学确诊为晚期胃癌患者的临床资料,其中观察组34例,采用自体DC-CIK联合XELOX方案(卡培他滨+奥沙利铂)化疗;对照组34例,单独采用XELOX方案化疗,疗程为2周期。治疗结束后对两组的近期疗效、不良反应、免疫功能进行评价。结果观察组客观缓解率为52.9%,对照组为41.2%,差异无统计学意义(P>0.05);观察组疾病控制率为79.4%,高于对照组(52.9%),差异有统计学意义(P<0.05)。观察组骨髓抑制、胃肠反应、神经毒性、手足综合征不良反应发生率均低于对照组(均P<0.05)。观察组T淋巴细胞亚群CD3+、CD4+、自然杀伤细胞(natural killer cell,NK)升高,CD4+/CD8+比值上升,与对照组比较差异均有统计学意义(均P<0.05)。对照组CD3+、NK治疗后较治疗前明显下降,差异均有统计学意义(均P<0.05)。结论 DC-CIK联合XELOX方案治疗晚期胃癌可以提高近期疗效,增强患者免疫功能,减轻化疗不良反应,值得临床推广。

Objective To evaluate the short-term efficacy of dendritic cells（ DC） and cytokine induced killer cells（ CIK） biotherapy combined with chemotherapy for patients with advanced gastric cancer. Methods Clinical data of 68 patients with advanced gastric cancer confirmed by pathology were analyzed. In this series,34 patients were treated with DC-CIK biotherapy combined with Xeloda and Oxaliplatin（ XELOX） regimen（ observation group）,while another 34 patients were given XELOX regimen alone（ control group）. Two cycles of treatment were administered to both groups,and short-term efficacy,side effects,and immunologic functions were compared between two groups. Results The objective response rates（ ORR） in observation group and control group were 52. 9% and 41. 2%,respectively（ P〉0. 05）. The disease control rate（ DCR） were 79. 4% in observation group and 52. 9% in control group（ P〈0. 05）. The incidences of side effects（ myelosuppression,gastroenteric reaction,neurotoxicity,hand-foot syndrome） in observation group were significantly lower than those in control group（ all P〈0. 05）. After treatment,the percentages of CD3＋,CD4＋and natural killer cells and the ratio of CD4＋/ CD8＋were significantly increased in observation group（ all P〈0. 05）; the percentages of CD3＋and NK cells were decreased in control group after treatment（ both P〈0. 05）. Conclusion DC-CIK biotherapy combined with XELOX regimen can increase short-term efficacy,enhance immune function,and alleviate side effects of patients with advanced gastric cancer.